ClinicalTrials.gg
Active, not recruitingNCT04718792Updated Jul 12, 2024

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

A Phase 2 interventional study of Psilocybin in Alcohol Use Disorder (AUD), sponsored by Anders Fink-Jensen, MD, DMSci. Active, not recruiting at 1 site in Denmark. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-12.

Sponsored by Anders Fink-Jensen, MD, DMSci · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.

Enrollment
16th of 17
10 · median 62
Started
2023
with 1 other
Phase 2
16 of 17
7 open now
Primary completion
2024-07
later than 0 of 12 live
Registered
5th of 17
by date
Lead sponsor
2 of 17
Anders Fink-Jensen, MD, DMSci

Among the 17 studies testing psilocybin in Alcoholism, this one is the 16th largest by enrollment, is one of 2 that started in 2023, is one of 16 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 5th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing psilocybin in Alcoholism, or all of them as a file.
02

Study summary

The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for treatment of AUD.

Read the detailed description

The investigators will evaluate the feasibility and safety of administering psilocybin to 10 patients diagnosed with AUD. Following informed consent, patients will be screened for eligibility as per in- and exclusion criteria and baseline values will be recorded as per outcome measures. All patients will receive a single administration of 25 mg of psilocybin. As per safety guidelines patients will be monitored the entire dosing session by study staff familiar with the psychedelic effects of psilocybin. In addition, the patients will meet before and after the dosing session with a psychologist connected to the study for preparation and post-session debriefing, respectively. During dosing session, the investigators will collect blood plasma psilocin levels in order to establish pharmacokinetics and an estimated brain 5-HT2AR occupancy. When the effects of psilocybin subside, the investigators will ask the patients to fill out questionnaires encapsulating the psychedelic experience. One week after drug administration the patients are required to meet for an end-of-study assessment of outcome measures including adverse events.

03

Conditions studied

  • Alcohol Use Disorder (AUD)

Keywords

  • psilocybin
  • alcohol use disorder
  • psychedelics
  • addiction
  • pharmacokinetics
  • psilocin
  • feasibility
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 20-70 years (both included).
  2. Body weight of 60-95 kg (both included).
  3. Diagnosed with AUD according to criteria and alcohol dependence according to ICD-10.
  4. Alcohol Use Disorder Identification Test (AUDIT) ≥ 15.
  5. ≥ 5 heavy drinking days.

Exclusion criteria

Exclusion Criteria:

  1. Personal or first-degree relatives with current or previous diagnosis within psychotic spectrum disorders or bipolar disorder.
  2. History of delirium tremens or alcohol withdrawal seizures.
  3. History of suicide attempt or present suicidal ideation.
  4. Withdrawal symptoms at inclusion, defined as a score higher than 9 on the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar).
  5. Present or former severe neurological disease including head trauma with loss of consciousness > 30 min.
  6. Impaired hepatic function (liver transaminases > 3 times upper normal limit).
  7. Cardiac problems defined as decompensated heart failure ( class III or IV), unstable angina pectoris and/or myocardial infarction within the last 12 months.
  8. Abnormal
  9. Impaired renal function ( \< 50 ml/min).
  10. Uncontrolled hypertension (systolic blood pressure >165 mmHg, diastolic blood pressure >95 mmHg).
  11. Pharmacotherapy against AUD including disulfiram, naltrexone, acamprosate and nalmefene or treatment with any of these compounds within 28 days prior to inclusion.
  12. Treatment with any serotonergic medication or any use of serotonergic psychedelics within 1 month prior to inclusion.
  13. Any other active substance use defined as a Drug Use Disorder Identification Test score > 6/2 (m/w) and substance use disorder based on investigator's clinical evaluation, except for nicotine.
  14. Women of who are pregnant, breastfeeding or have intention of becoming pregnant or are not using adequate measures considered highly effective61.
  15. to the active substance or to any of the .
  16. Unable to speak and/or understand Danish.
  17. Any condition that the investigator feels would interfere with trial participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Psilocybin

    10 patients will receive a single administration of psilocybin

    Drug: Psilocybin

Interventions

  • A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)

06

What researchers measure

Primary outcomes

  1. Safety: Adverse events associated with administration of psilocybin in patients diagnosed with alcohol use disorder

    Assessment of the incidence and severity of expected and unexpected adverse events

    Time frame: 12 week after drug administration

Secondary outcomes

  1. Feasibility: Proportion of participants who complete

    Proportion of included patients who complete the planned procedures

    Time frame: 1 week after drug administration

  2. Pharmacokinetic parameter of psilocin: Cmax

    Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data. Blood samples will be drawn with intervals of 20 minutes

    Time frame: From drug administration and 360 minutes after.

  3. Pharmacokinetic parameter of psilocin: Tmax

    Tmax: Time to reach maximum concentration of plasma psilocin determined from concentrations-versus-time data. Blood samples will be drawn with intervals of 20 minutes

    Time frame: From drug administration to 360 minutes after.

  4. Pharmacokinetic parameter of psilocin: AUC

    AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule.

    Time frame: From drug administration to 360 minutes after.

  5. Pharmacokinetic parameter of brain-derived neurotropic factor

    Acute and subacute changes in plasma and wholeblod brain-derived neurotropic factor (BDNF)

    Time frame: From drug administration to 360 minutes after and 1 week after

  6. Pharmacokinetic parameter of cytokines

    Acute and subacute changes in plasma cytokines including tumour necrosis factor alpha, interleukin-4 and 6.

    Time frame: From drug administration to 360 minutes after and 1 week after

  7. Pharmacodynamics of cardiovascular measures

    Acute changes in systolic and diastolic blood pressure (mmHg)

    Time frame: From drug administration to 360 minutes after

  8. Pharmacodynamics of cardiovascular measures

    Acute changes in heart rate (beats per minute)

    Time frame: From drug administration to 360 minutes after

  9. Subjective effects of psilocybin: Intensity

    Intensity of the drug effect will be assessed with intervals of 20 minutes asking the patients "How intense is the experience right now" on a 0-10 Likert scale where 0 = not intense at all, 10 = very intense.

    Time frame: From drug administration to 8 hours after

  10. Subjective effects of psilocybin: Mystical Experience

    Experiential aspects of psilocybin measured by The Mystical Experience Questionnaire (MEQ). The patients are asked to rate the items on a 6-point scale going from 0= none; not at all to 5=extreme; more than ever before in my life and stronger than 4.

    Time frame: 8 hours after drug administration

  11. Subjective effects of psilocybin: Altered States of Consciousness

    Experiential aspects of psilocybin measured by the 11-Dimensional Altered State of Consciousness scale (11-DASC). The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).

    Time frame: 8 hours after drug administration

  12. Subjective effects of psilocybin: Awe Experience

    Experiential aspects of psilocybin measured by the Awe Experience Scale. The patients are asked to rate the items on a 7-point scale going from 1= Strongly Disagree to 7= Strongly Agree.

    Time frame: 8 hours after drug administration

  13. Subjective effects of psilocybin: Ego Dissolution

    Experiential aspects of psilocybin measured by the Ego Dissolution Inventory. The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).

    Time frame: 8 hours after drug administration

  14. Change in heavy drinking days

    Change in heavy drinking day, defined as consuming 60/48 g (men/women) of alcohol or more on any day, in the past 28 days as quantified by the Timeline Followback Method

    Time frame: Baseline, 4, 12 and 52 weeks after drug administration

  15. Change in drinks per day

    Change in drinks per day in the past 28 days as quantified by the Timeline Followback Method

    Time frame: Baseline, 4, 12 and 52 weeks after drug administration

  16. Change in drinking days

    Change in drinking days in the past 28 days as quantified by the Timeline Followback Method

    Time frame: Baseline, 4, 12 and 52 weeks after drug administration

  17. Change in alcohol use

    Change in self-reported alcohol use measured by the Alcohol Use Identification Test (AUDIT). The AUDIT has 10 questions and the possible responses to each question are scored 0, 1, 2, 3 or 4, with the exception of questions 9 and 10 which have possible responses of 0, 2 and 4. The range of possible scores is from 0 to 40 where 0 indicates an abstainer who has never had any problems from alcoho

    Time frame: Baseline, 12 and 52 week after drug administration

  18. Change in craving

    Change in self-reported craving measured by the Penn Alcohol Craving Scale (PACS). The patients are asked to rate the items on a 7-point scale going from 0= Never to 6= Nearly all of the time.

    Time frame: Baseline, 1 week, 4 week, 12 and 52 week after drug administration

  19. Change in self-efficacy

    Change in self-reported self-efficacy measured by the Alcohol Abstinence Self-efficacy (AASE). The patients are asked to rate the items on a 5-point scale going from 1= not at all to 5= extremely.

    Time frame: Baseline, 1 week, 4 week, 12 and 52 week after drug administration

  20. Change in mindfulness

    Change in self-reported mindfulness measured by the Mindful Attention Awareness Scale (MAAS). The patients are asked to rate the items on a 6-point scale going from 1= Almost always to 6= Almost never.

    Time frame: Baseline, 1 week, 4 week, 12 and 52 week after drug administration

  21. Change in psychological flexibility

    Change in self-reported flexibility measured by the Acceptance and Action Questionnaire (AAQ). The patients are asked to rate the items on a 7-point scale going from 1= Never true to 7= Always true.

    Time frame: Baseline, 1 week, 4 week, 12 and 52 week after drug administration

  22. Change in depressive symptoms

    Change in self-reported depression symptoms measured by the Major Depressive Inventory (MDI). The patients are asked to rate the items on a 6-point scale going from 1= Always to 7= Never.

    Time frame: Baseline, 1 week, 4 week, 12 and 52 week after drug administration

  23. Expectancy to treatment

    Assessment of the patients expectations before the treatment as measured by the Stanford Expectations of Treatment Scale (SETS).

    Time frame: Baseline

  24. Persisting Effects

    Assessment of eight categories of possible changes in attitudes, mood, social effects, and behavior after drug administration

    Time frame: 4, 12 and 52 weeks after drug administration

  25. Change in personality traits

    Change in personality traits as measured by NEO Five-Factor Inventory-3 (NEO-FFI-3). NEO-FFI is 60 items measuring five dimensions of personality: Agreeableness (A), Conscientiousness (C), Neuroticism (N), Extraversion (E), and Openness to Experience (O)

    Time frame: Baseline and Week 12 after drug administration

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jul 2024, 17 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 17 months is below that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2021
First posted
Jan 22, 2021
StartActual
Feb 9, 2023
Primary completionEst.
Jul 21, 2024
CompletionEst.
Jul 21, 2024
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04718792
Lead sponsor
Anders Fink-Jensen, MD, DMSci
Collaborators
The Neurobiology Research Unit at Copenhagen University Hospital Rigshospitalet
Responsible party
Anders Fink-Jensen, MD, DMSci (Professor, Psychiatric Centre Rigshospitalet) — Sponsor-investigator
First posted
Jan 22, 2021
Start date
Feb 9, 2023
Primary completion
Jul 21, 2024 (estimated)
Completion
Jul 21, 2024 (estimated)
Last update
Jul 12, 2024

Study contacts

Anders Fink-Jensen, Professor
principal investigator · Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion